

James Chih-Hsin Yang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5070242/james-chih-hsin-yang-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241
papers

20,037
citations

57
h-index

139
g-index

257
ext. papers

24,242
ext. citations

5.5
avg, IF

6.54
L-index

#	Paper	IF	Citations
241	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3327-34	2.2	2262
240	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1689-99	59.2	1447
239	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). <i>Journal of Clinical Oncology</i> , 2011 , 29, 2866-74	2.2	1102
238	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2015 , 16, 141-51	21.7	1081
237	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology, The</i> , 2016 , 17, 1497-1508	21.7	954
236	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 528-38	21.7	777
235	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology, The</i> , 2016 , 17, 577-89	21.7	691
234	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3375-82	2.2	605
233	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 661-8	2.2	441
232	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 403-407	8.9	432
231	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2027-2039	59.2	427
230	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 433-40	2.2	420
229	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 595-605	9.7	402
228	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016 , 22, 5130-5140	12.9	397
227	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2127-33	11.5	366
226	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
225	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 539-48	21.7	331

224	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 990-8	21.7	291
223	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 210-216	13.4	277
222	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3342-50	2.2	222
221	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1958-65	2.2	211
220	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016 , 7, 12404-13	3.3	165
219	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2369-2379	2.2	160
218	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1405-1411	2.2	152
217	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology, The</i> , 2020 , 21, 373-386	21.7	148
216	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3101-3109	2.2	146
215	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 567-572	8.9	139
214	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 793-799	8.9	139
213	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 124-129	8.9	137
212	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	136
211	ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3926-34	2.2	134
210	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 194-207	8.9	132
209	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4079-4085	2.2	124
208	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3258-66	2.2	107
207	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Letters</i> , 2013 , 328, 144-51	9.9	106

206	Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1872-80	8.9	106
205	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015 , 27, 94-101	4.2	102
204	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9503-9503	2.2	99
203	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4027-4034	2.2	97
202	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1754-61	8.9	96
201	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 107-116	35.1	86
200	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 933-939	8.9	83
199	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 633-643	8.9	82
198	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 803-815	8.9	77
197	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1745-53	8.9	74
196	Diarrhea associated with afatinib: an oral ErbB family blocker. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 729-36	3.5	73
195	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 553-559	8.9	66
194	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1132-1143	35.1	66
193	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8009-8009	2.2	63
192	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
191	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3391-3402	2.2	62
190	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017 , 116, 175-185	8.7	61
189	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. <i>Molecular Oncology</i> , 2013 , 7, 112-20	7.9	61

188	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , 2011 , 11, 430	4.8	59
187	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. <i>Science Translational Medicine</i> , 2016 , 8, 368ra172	17.5	58
186	Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1171-9	8.9	57
185	Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). <i>Journal of Thoracic Oncology</i> , 2013 , 8, 229-37	8.9	57
184	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 891-902	35.1	56
183	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1552-1560	8.9	55
182	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2020-2020	2.2	54
181	Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. <i>Clinical Cancer Research</i> , 2011 , 17, 6459-66	12.9	53
180	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500	2.2	53
179	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9002-9002	2.2	53
178	Precision Management of Advanced Non-Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020 , 71, 117-136	17.4	52
177	Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1418-25	8.9	51
176	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014 , 15, 173-81	4.9	50
175	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015 , 6, 10415-31	3.3	49
174	Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 973-81	8.9	49
173	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016 , 94, 46-53	5.9	48
172	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1140-52	8.9	46
171	Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. <i>Clinical Cancer Research</i> , 2012 , 18, 3470-7	12.9	46

170	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1897-1905	8.9	45
169	Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 36, 387-396	5.6	42
168	Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1385-92	8.9	41
167	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015 , 88, 208-14	5.9	41
166	Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9016-9016	2.2	41
165	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1247-1256	8.9	40
164	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018 , 125, 273-281	5.9	40
163	Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. <i>Lung Cancer</i> , 2014 , 85, 230-8	5.9	40
162	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018 , 19, e465-e479	4.9	39
161	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , 2014 , 83, 174-81	5.9	36
160	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1907-1918	8.9	36
159	Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1720-5	8.9	35
158	Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1663-9	8.9	35
157	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Biomedical Science</i> , 2016 , 23, 86	13.3	35
156	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018 , 9, 1813-1820	4.5	34
155	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. <i>PLoS ONE</i> , 2015 , 10, e0119135	3.7	34
154	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013 , 82, 420-5	5.9	32
153	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019 , 144, 2887-2896	7.5	32

152	Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. <i>Lung Cancer</i> , 2017 , 110, 7-13	5.9	31
151	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1156-1169	3.8	30
150	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014 , 50, 2219-30	7.5	29
149	Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 50-61	8.9	29
148	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8017-8027	3.7	27
147	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 324-332.e1	4.9	26
146	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9044-9044	2.2	26
145	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 162-168	8.9	26
144	Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 38-45	3.6	25
143	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020 , 38, 99-110	4.3	25
142	Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One Helical Cell-Penetrating Peptide or Glutathione and Tween 80. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	24
141	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1569-1579	4.9	24
140	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018 , 78, 3350-3362	10.1	23
139	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016 , 17, e77-e94	4.9	23
138	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012 , 77, 346-52	5.9	22
137	Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8004-8004	2.2	22
136	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. <i>PLoS ONE</i> , 2013 , 8, e80276	3.7	22
135	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10581	12	21

134	Survival of patients with small cell lung carcinoma in Taiwan. <i>Oncology</i> , 2012 , 82, 19-24	3.6	21
133	First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919836374	5.4	20
132	Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. <i>Journal of Nanobiotechnology</i> , 2019 , 17, 89	9.4	20
131	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017 , 22, 1075-1083	5.7	19
130	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2013 , 49, 106-14	7.5	19
129	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 274-90	5.4	18
128	Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3662-3670	2.2	18
127	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 117, 107-115	7.5	18
126	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. <i>Lung Cancer</i> , 2019 , 133, 103-109	5.9	17
125	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 126-131	5.9	17
124	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 27-34	4.9	17
123	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018 , 126, 368-374	5.3	17
122	Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 418-24	4.9	17
121	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014 , 32, 445-51	4.3	17
120	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8013-8013	2.2	17
119	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 91-100	8.9	17
118	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 992-1002	12.9	17
117	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1588-1594	8.9	16

116	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 663-673	10.2	16
115	Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e95-e96	8.9	16
114	Phase I Study of the Focal Adhesion Kinase Inhibitor BI-53520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. <i>Targeted Oncology</i> , 2019 , 14, 57-65	5	15
113	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 792-800	8.9	15
112	AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8016-8016	2.2	15
111	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2006-2006	2.2	15
110	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. <i>PLoS ONE</i> , 2015 , 10, e0145936	3.7	15
109	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019 , 133, 10-19	5.9	14
108	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018 , 19, e361-e372	4.9	14
107	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9022-9022	2.2	14
106	Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 38-42	8.7	14
105	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. <i>Expert Review of Respiratory Medicine</i> , 2017 , 11, 51-55	3.8	13
104	Profile of the theascreen [®] EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1251-1257	3.8	13
103	Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	13
102	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 324-343	8.9	13
101	Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9077-9077	2.2	13
100	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. <i>Oncologist</i> , 2019 , 24, e1417-e1423	5.7	13
99	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017 , 19, 4	6.3	12

98	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. <i>Clinical Drug Investigation</i> , 2018 , 38, 319-331	3.2	12
97	Opportunities of circulating tumor DNA in lung cancer. <i>Cancer Treatment Reviews</i> , 2019 , 78, 31-41	14.4	12
96	Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1411-7	8.9	12
95	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. <i>Drugs</i> , 2013 , 73, 357-69	12.1	12
94	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7500-LBA7500	2.2	12
93	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9517-9517	2.2	12
92	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017 , 8, 41474-41486	3.3	12
91	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9008-9008	2.2	12
90	First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. <i>Clinical Lung Cancer</i> , 2016 , 17, 150-60	4.9	12
89	Second-line treatment of T790M-negative non-small cell lung cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919890286	5.4	12
88	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018 , 11, 131-141	3.7	12
87	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020 , 25, 702-711	5.7	11
86	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020 , 122, 1324-1332	8.7	11
85	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase III Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 370-9	8.9	11
84	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. <i>Supportive Care in Cancer</i> , 2014 , 22, 1189-97	3.9	11
83	Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator choice chemotherapy following progression on afatinib monotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1557-1567	2.2	11
82	Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11506-11506	2.2	11
81	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2069-2069	2.2	11

80	First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9094-9094	2.2	11
79	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9001-9001	2.2	11
78	The Role of Interleukin 1β in the Pathogenesis of Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100001	1.4	10
77	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, e103-e112	4.9	10
76	Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. <i>Clinical Cancer Research</i> , 2013 , 19, 5292-9	12.9	10
75	Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: an east asian population-based study. <i>Oncologist</i> , 2012 , 17, 1294-302	5.7	10
74	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9046-9046	2.2	10
73	Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2021 , 17, 965-977	3.6	10
72	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. <i>Oncologist</i> , 2015 , 20, 1051-7	5.7	9
71	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 513-521	5	9
70	Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018 , 109, 2852-2862	6.9	9
69	Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. <i>Clinical Lung Cancer</i> , 2019 , 20, e609-e618	4.9	9
68	AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8000-8000	2.2	9
67	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020 , 139, 22-27	5.9	9
66	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. <i>Clinical Lung Cancer</i> , 2015 , 16, 137-43	4.9	8
65	Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9061-9061	2.2	8
64	24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9026-9026	2.2	8
63	Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9094-9094	2.2	8

62	Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. <i>Journal of the Formosan Medical Association</i> , 2018 , 117, 326-331	3.2	7
61	Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. <i>Journal of Neuro-Oncology</i> , 2013 , 115, 61-70	4.8	7
60	CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021 , 41, 1231-1242	2.3	7
59	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2013 , 9, 991-1003	3.6	6
58	A selective ALK inhibitor in ALK-rearranged patients. <i>Lancet Oncology, The</i> , 2013 , 14, 564-5	21.7	6
57	Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. <i>Drugs</i> , 2011 , 71, 79-88	12.1	6
56	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 22, 76-82	4.6	6
55	Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20501-e20501	2.2	5
54	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9072-9072	3.2	5
53	Tepotinib Efficacy and Safety in Patients with Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
52	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , 2016 , 7, 1515-23	4.5	5
51	Safety of gefitinib in non-small cell lung cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 993-1000	10.0	5
50	Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (-)Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. <i>Lung Cancer: Targets and Therapy</i> , 2019 , 10, 125-130	2.9	5
49	Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 230-236	3.2	5
48	The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020 , 59, 96-100	3.2	5
47	Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 995-1004	3.2	4
46	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1817-1826	3.2	4
45	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 851-864	4	4

44	The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.. <i>Journal of Clinical Oncology</i> , 2015 , <i>33</i> , 8072-8072	2.2	4
43	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , <i>33</i> , 8073-8073	2.2	4
42	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , <i>30</i> , 7558-7558	2.2	3
41	Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , <i>36</i> , 9053-9053	2.2	3
40	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , 2018 , <i>36</i> , 9071-9071	2.2	3
39	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , <i>12</i> , 17588359209461564	5.4	3
38	The Inhibition of Wnt Restrain KRAS-Driven Metastasis in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020 , <i>12</i> ,	6.6	3
37	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021 , <i>2</i> , 100114	1.4	3
36	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021 , <i>17</i> , 4237-4247	3.6	3
35	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. <i>JAMA Oncology</i> , 2018 , <i>4</i> , 1138-1139	13.4	2
34	Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.. <i>Journal of Clinical Oncology</i> , 2020 , <i>38</i> , 3588-3588	2.2	2
33	Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2020 , <i>38</i> , 9574-9574	2.2	2
32	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , <i>38</i> , TPS9075-TPS9075	2.2	2
31	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. <i>Cancer Research and Treatment</i> , 2020 , <i>52</i> , 284-291	5.2	2
30	A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).. <i>Journal of Clinical Oncology</i> , 2020 , <i>38</i> , TPS9631-TPS9631	2.2	2
29	Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. <i>Lung Cancer</i> , 2020 , <i>148</i> , 177-178	5.9	2
28	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2021 , <i>154</i> , 113-117	5.9	2
27	Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in -Mutant Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021 , <i>13</i> ,	6.6	2

26	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100140	1.4	2
25	Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?. <i>Lancet Oncology</i> , 2019 , 20, 602-603	21.7	1
24	Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2016 , 9, 474-480 ¹		1
23	Interview: Changing advanced lung cancer into chronic disease. <i>Lung Cancer Management</i> , 2014 , 3, 23-28 ^{2,6}		1
22	A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19013-e19013	2.2	1
21	Effect of itraconazole or rifampicin on the pharmacokinetics (PK) of osimertinib (AZD9291).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14100-e14100	2.2	1
20	Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8547-8547	2.2	1
19	TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8109-TPS8109	2.2	1
18	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20507-e20507	2.2	1
17	HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS9139-TPS9139 ^{2,2}	2.2	1
16	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Mutations: An Updated Database of 1023 Cases Brief Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 834704	5.3	1
15	Reply to E.R. Haspinger et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 863-4	2.2	0
14	Reply to F. De Marinis et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 865	2.2	0
13	Real-world insights into patients with advanced NSCLC and MET alterations. <i>Lung Cancer</i> , 2021 , 159, 96-106	5.9	0
12	Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 694-695 ^{2,2}		
11	Angiokinase inhibitors in non-small-cell lung cancer. <i>Clinical Investigation</i> , 2015 , 5, 47-59		
10	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. <i>Translational Lung Cancer Research</i> , 2012 , 1, 227-9	4.4	
9	457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC) 2021 , 9, A485-A485		

- 8 Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET+), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm+) and progression on gefitinib.. *Journal of Clinical Oncology*, **2014**, 32, TPS8121-TPS8121 2.2
- 7 Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. *Journal of Clinical Oncology*, **2014**, 32, TPS2631-TPS2631 2.2
- 6 The impact of diabetes mellitus on early cervical cancer in Bia: A population-based cohort study.. *Journal of Clinical Oncology*, **2014**, 32, e16501-e16501 2.2
- 5 Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis.. *Journal of Clinical Oncology*, **2015**, 33, e19061-e19061 2.2
- 4 Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. *Journal of Clinical Oncology*, **2015**, 33, 2012-2013 2.2
- 3 TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy.. *Journal of Clinical Oncology*, **2015**, 33, 2012-2013 2.2
- 2 Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. *JTO Clinical and Research Reports*, **2021**, 2, 100142 1.4
- 1 Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M-Positive NSCLC. *JTO Clinical and Research Reports*, **2021**, 2, 100099 1.4